Tags : Charles River

Weekly Snapshot

PharmaShots Weekly Snapshots (May 17 – 21, 2021)

BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Published: May 21, 2021 | Tags: BeiGene, Tislelizumab, CT, P-III, RATIONALE 309 Study, Recurrent, Metastatic Nasopharyngeal Cancer Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR […]Read More

Biotech M&A

Charles River to Acquire Vigene Biosciences for $292.5M

Shots: Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5M based on future performance The transaction is expected to be close in Q3’21. The acquisition will allow Charles River to boost its gene therapy capabilities […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Biotech

Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery

Shots: The collaboration provides Charles River’s client access to Fios Genomics’ expertise in bioinformatics, statistics and biology, assisting the sourcing and analysis datasets associated with the drug development including microarrays, NGS, proteomics, metabolomics, epigenetics and associated meta-data The agreement merges Fios’ biologically-relevant insights with Charles River’s drug discovery and development platform and the scientific expertise […]Read More

M&A

Charles River to Acquire HemaCare Corporation for $380M

Shots: Charles River to acquire HemaCare in all cash transactions at $25.40 /share, making a total deal value $380M with a premium of 33% to HemaCare’s volume-weighted average stock price over the last 60 trading days. The transaction is expected to be completed in Q1’20 The focus of the acquisition is to expand Charles River’s […]Read More